A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin
Background This study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America. Methods Diff...
Gespeichert in:
| Veröffentlicht in: | Diabetes/metabolism research and reviews 2017-03, Vol.33 (3), p.np-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | np |
| container_title | Diabetes/metabolism research and reviews |
| container_volume | 33 |
| creator | Raccah, Denis Chou, Engels Colagiuri, Stephen Gaàl, Zsolt Lavalle, Fernando Mkrtumyan, Ashot Nikonova, Elena Tentolouris, Nikolaos Vidal, Josep Davies, Melanie |
| description | Background
This study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America.
Methods
Different levels of evidence were used as available for each country/region, with data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as “well controlled” (glycated hemoglobin [HbA1c] at target [ |
| doi_str_mv | 10.1002/dmrr.2858 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5347910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4317662381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5048-aaa7a75488fc661f85bd7bade44bd3e5f33407f742eff1c535fd587f070794263</originalsourceid><addsrcrecordid>eNqNks-KFDEQxhtR3HX14AtIwIseZjdJJ53MRVjWv7AiLHoO6aSynaU7aZP0LPN6PpkZZx1UUDxVQf34qurja5qnBJ8SjOmZnVI6pZLLe80x4RSvBO_w_UPP6VHzKOcbjHHLOvawOaKiw52U8rj5do6ux9jrEeWy2C2KDpUB0BImKCgAWORiqsjWwOQNMjGUFEekg0VzAutNqWOndyUjPcVwjWZdPISS0a0vAyrbGRBF1useCmQ0wTj6stTpENGgN4C0GTxs6qY4Fz_VS5zOxe-ERp0nXZcvJmY47I4B9TpXzoe8jD48bh44PWZ4cldPmi9v33y-eL-6_PTuw8X55cpwzORKay204ExKZ7qOOMl7K3ptgbHetsBd2zIsnGAUnCOGt9xZLoXDAos1o1170rza685LP4E19cekRzWnenTaqqi9-n0S_KCu40bxlok1wVXgxZ1Ail8XyEVNPpvqhw4Ql6yIFEJS3BH-H2jLGaFM0Io-_wO9iUsK1QlF1i2n67bD8p-UFFRITBmr1Ms9ZVLMOYE7fEew2kVN7aKmdlGr7LNf7TiQP7NVgbM9cOtH2P5dSb3-eHX1Q_I76QriYQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1872780244</pqid></control><display><type>article</type><title>A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Raccah, Denis ; Chou, Engels ; Colagiuri, Stephen ; Gaàl, Zsolt ; Lavalle, Fernando ; Mkrtumyan, Ashot ; Nikonova, Elena ; Tentolouris, Nikolaos ; Vidal, Josep ; Davies, Melanie</creator><creatorcontrib>Raccah, Denis ; Chou, Engels ; Colagiuri, Stephen ; Gaàl, Zsolt ; Lavalle, Fernando ; Mkrtumyan, Ashot ; Nikonova, Elena ; Tentolouris, Nikolaos ; Vidal, Josep ; Davies, Melanie</creatorcontrib><description>Background
This study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America.
Methods
Different levels of evidence were used as available for each country/region, with data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as “well controlled” (glycated hemoglobin [HbA1c] at target [<7%]), “residual hyperglycemia” (fasting plasma glucose [FPG] but not HbA1c at target [FPG <7.2/7.8 mmol/L, <130/140 mg/dL, depending on country‐specific recommendations]), or “uncontrolled” (both FPG and HbA1c above target). Predictor factors were identified from the RCT data set using logistic regression analysis.
Results
RCT data showed that 16.9% to 28.0%, 42.7% to 54.4%, and 16.9% to 38.1% of patients with T2DM had well‐controlled glycemia, residual hyperglycemia, and uncontrolled hyperglycemia, respectively. In CTRs, respective ranges were 21.8% to 33.6%, 31.5% to 35.6%, and 30.7% to 46.8%, and in EMR databases were 4.4% to 21.0%, 23.9% to 31.8%, and 53.6% to 63.8%. Significant predictor factors of residual hyperglycemia identified from RCT data included high baseline HbA1c (all countries/regions except Brazil), high baseline FPG (United Kingdom/Japan), longer duration of diabetes (Brazil), and female sex (Europe/Latin America).
Conclusions
Irrespective of intrinsic differences between data sources, 24% to 54% of patients with T2DM globally had residual hyperglycemia with HbA1c not at target, despite achieving FPG control, indicating a significant unmet need for postprandial glycemic control.</description><identifier>ISSN: 1520-7552</identifier><identifier>EISSN: 1520-7560</identifier><identifier>DOI: 10.1002/dmrr.2858</identifier><identifier>PMID: 27606888</identifier><identifier>CODEN: DMRRFM</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Biomarkers - analysis ; Blood glucose ; Blood Glucose - metabolism ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; Electronic medical records ; Fasting - physiology ; fasting plasma glucose ; Global Health ; Glucose ; Glucose monitoring ; Glycated Hemoglobin A - analysis ; glycemic control ; Humans ; Hyperglycemia ; Hyperglycemia - prevention & control ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin - therapeutic use ; insulin therapy ; Needs Assessment ; postprandial glucose ; Prognosis ; residual hyperglycemia ; type 2 diabetes mellitus</subject><ispartof>Diabetes/metabolism research and reviews, 2017-03, Vol.33 (3), p.np-n/a</ispartof><rights>2016 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5048-aaa7a75488fc661f85bd7bade44bd3e5f33407f742eff1c535fd587f070794263</citedby><cites>FETCH-LOGICAL-c5048-aaa7a75488fc661f85bd7bade44bd3e5f33407f742eff1c535fd587f070794263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fdmrr.2858$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fdmrr.2858$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27606888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raccah, Denis</creatorcontrib><creatorcontrib>Chou, Engels</creatorcontrib><creatorcontrib>Colagiuri, Stephen</creatorcontrib><creatorcontrib>Gaàl, Zsolt</creatorcontrib><creatorcontrib>Lavalle, Fernando</creatorcontrib><creatorcontrib>Mkrtumyan, Ashot</creatorcontrib><creatorcontrib>Nikonova, Elena</creatorcontrib><creatorcontrib>Tentolouris, Nikolaos</creatorcontrib><creatorcontrib>Vidal, Josep</creatorcontrib><creatorcontrib>Davies, Melanie</creatorcontrib><title>A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin</title><title>Diabetes/metabolism research and reviews</title><addtitle>Diabetes Metab Res Rev</addtitle><description>Background
This study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America.
Methods
Different levels of evidence were used as available for each country/region, with data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as “well controlled” (glycated hemoglobin [HbA1c] at target [<7%]), “residual hyperglycemia” (fasting plasma glucose [FPG] but not HbA1c at target [FPG <7.2/7.8 mmol/L, <130/140 mg/dL, depending on country‐specific recommendations]), or “uncontrolled” (both FPG and HbA1c above target). Predictor factors were identified from the RCT data set using logistic regression analysis.
Results
RCT data showed that 16.9% to 28.0%, 42.7% to 54.4%, and 16.9% to 38.1% of patients with T2DM had well‐controlled glycemia, residual hyperglycemia, and uncontrolled hyperglycemia, respectively. In CTRs, respective ranges were 21.8% to 33.6%, 31.5% to 35.6%, and 30.7% to 46.8%, and in EMR databases were 4.4% to 21.0%, 23.9% to 31.8%, and 53.6% to 63.8%. Significant predictor factors of residual hyperglycemia identified from RCT data included high baseline HbA1c (all countries/regions except Brazil), high baseline FPG (United Kingdom/Japan), longer duration of diabetes (Brazil), and female sex (Europe/Latin America).
Conclusions
Irrespective of intrinsic differences between data sources, 24% to 54% of patients with T2DM globally had residual hyperglycemia with HbA1c not at target, despite achieving FPG control, indicating a significant unmet need for postprandial glycemic control.</description><subject>Biomarkers - analysis</subject><subject>Blood glucose</subject><subject>Blood Glucose - metabolism</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Electronic medical records</subject><subject>Fasting - physiology</subject><subject>fasting plasma glucose</subject><subject>Global Health</subject><subject>Glucose</subject><subject>Glucose monitoring</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>glycemic control</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hyperglycemia - prevention & control</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin - therapeutic use</subject><subject>insulin therapy</subject><subject>Needs Assessment</subject><subject>postprandial glucose</subject><subject>Prognosis</subject><subject>residual hyperglycemia</subject><subject>type 2 diabetes mellitus</subject><issn>1520-7552</issn><issn>1520-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNqNks-KFDEQxhtR3HX14AtIwIseZjdJJ53MRVjWv7AiLHoO6aSynaU7aZP0LPN6PpkZZx1UUDxVQf34qurja5qnBJ8SjOmZnVI6pZLLe80x4RSvBO_w_UPP6VHzKOcbjHHLOvawOaKiw52U8rj5do6ux9jrEeWy2C2KDpUB0BImKCgAWORiqsjWwOQNMjGUFEekg0VzAutNqWOndyUjPcVwjWZdPISS0a0vAyrbGRBF1useCmQ0wTj6stTpENGgN4C0GTxs6qY4Fz_VS5zOxe-ERp0nXZcvJmY47I4B9TpXzoe8jD48bh44PWZ4cldPmi9v33y-eL-6_PTuw8X55cpwzORKay204ExKZ7qOOMl7K3ptgbHetsBd2zIsnGAUnCOGt9xZLoXDAos1o1170rza685LP4E19cekRzWnenTaqqi9-n0S_KCu40bxlok1wVXgxZ1Ail8XyEVNPpvqhw4Ql6yIFEJS3BH-H2jLGaFM0Io-_wO9iUsK1QlF1i2n67bD8p-UFFRITBmr1Ms9ZVLMOYE7fEew2kVN7aKmdlGr7LNf7TiQP7NVgbM9cOtH2P5dSb3-eHX1Q_I76QriYQ</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Raccah, Denis</creator><creator>Chou, Engels</creator><creator>Colagiuri, Stephen</creator><creator>Gaàl, Zsolt</creator><creator>Lavalle, Fernando</creator><creator>Mkrtumyan, Ashot</creator><creator>Nikonova, Elena</creator><creator>Tentolouris, Nikolaos</creator><creator>Vidal, Josep</creator><creator>Davies, Melanie</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201703</creationdate><title>A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin</title><author>Raccah, Denis ; Chou, Engels ; Colagiuri, Stephen ; Gaàl, Zsolt ; Lavalle, Fernando ; Mkrtumyan, Ashot ; Nikonova, Elena ; Tentolouris, Nikolaos ; Vidal, Josep ; Davies, Melanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5048-aaa7a75488fc661f85bd7bade44bd3e5f33407f742eff1c535fd587f070794263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biomarkers - analysis</topic><topic>Blood glucose</topic><topic>Blood Glucose - metabolism</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Electronic medical records</topic><topic>Fasting - physiology</topic><topic>fasting plasma glucose</topic><topic>Global Health</topic><topic>Glucose</topic><topic>Glucose monitoring</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>glycemic control</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hyperglycemia - prevention & control</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin - therapeutic use</topic><topic>insulin therapy</topic><topic>Needs Assessment</topic><topic>postprandial glucose</topic><topic>Prognosis</topic><topic>residual hyperglycemia</topic><topic>type 2 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raccah, Denis</creatorcontrib><creatorcontrib>Chou, Engels</creatorcontrib><creatorcontrib>Colagiuri, Stephen</creatorcontrib><creatorcontrib>Gaàl, Zsolt</creatorcontrib><creatorcontrib>Lavalle, Fernando</creatorcontrib><creatorcontrib>Mkrtumyan, Ashot</creatorcontrib><creatorcontrib>Nikonova, Elena</creatorcontrib><creatorcontrib>Tentolouris, Nikolaos</creatorcontrib><creatorcontrib>Vidal, Josep</creatorcontrib><creatorcontrib>Davies, Melanie</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes/metabolism research and reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raccah, Denis</au><au>Chou, Engels</au><au>Colagiuri, Stephen</au><au>Gaàl, Zsolt</au><au>Lavalle, Fernando</au><au>Mkrtumyan, Ashot</au><au>Nikonova, Elena</au><au>Tentolouris, Nikolaos</au><au>Vidal, Josep</au><au>Davies, Melanie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin</atitle><jtitle>Diabetes/metabolism research and reviews</jtitle><addtitle>Diabetes Metab Res Rev</addtitle><date>2017-03</date><risdate>2017</risdate><volume>33</volume><issue>3</issue><spage>np</spage><epage>n/a</epage><pages>np-n/a</pages><issn>1520-7552</issn><eissn>1520-7560</eissn><coden>DMRRFM</coden><abstract>Background
This study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America.
Methods
Different levels of evidence were used as available for each country/region, with data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as “well controlled” (glycated hemoglobin [HbA1c] at target [<7%]), “residual hyperglycemia” (fasting plasma glucose [FPG] but not HbA1c at target [FPG <7.2/7.8 mmol/L, <130/140 mg/dL, depending on country‐specific recommendations]), or “uncontrolled” (both FPG and HbA1c above target). Predictor factors were identified from the RCT data set using logistic regression analysis.
Results
RCT data showed that 16.9% to 28.0%, 42.7% to 54.4%, and 16.9% to 38.1% of patients with T2DM had well‐controlled glycemia, residual hyperglycemia, and uncontrolled hyperglycemia, respectively. In CTRs, respective ranges were 21.8% to 33.6%, 31.5% to 35.6%, and 30.7% to 46.8%, and in EMR databases were 4.4% to 21.0%, 23.9% to 31.8%, and 53.6% to 63.8%. Significant predictor factors of residual hyperglycemia identified from RCT data included high baseline HbA1c (all countries/regions except Brazil), high baseline FPG (United Kingdom/Japan), longer duration of diabetes (Brazil), and female sex (Europe/Latin America).
Conclusions
Irrespective of intrinsic differences between data sources, 24% to 54% of patients with T2DM globally had residual hyperglycemia with HbA1c not at target, despite achieving FPG control, indicating a significant unmet need for postprandial glycemic control.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27606888</pmid><doi>10.1002/dmrr.2858</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-7552 |
| ispartof | Diabetes/metabolism research and reviews, 2017-03, Vol.33 (3), p.np-n/a |
| issn | 1520-7552 1520-7560 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5347910 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biomarkers - analysis Blood glucose Blood Glucose - metabolism Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Electronic medical records Fasting - physiology fasting plasma glucose Global Health Glucose Glucose monitoring Glycated Hemoglobin A - analysis glycemic control Humans Hyperglycemia Hyperglycemia - prevention & control Hypoglycemic Agents - therapeutic use Insulin Insulin - therapeutic use insulin therapy Needs Assessment postprandial glucose Prognosis residual hyperglycemia type 2 diabetes mellitus |
| title | A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T07%3A36%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20global%20study%20of%20the%20unmet%20need%20for%20glycemic%20control%20and%20predictor%20factors%20among%20patients%20with%20type%202%20diabetes%20mellitus%20who%20have%20achieved%20optimal%20fasting%20plasma%20glucose%20control%20on%20basal%20insulin&rft.jtitle=Diabetes/metabolism%20research%20and%20reviews&rft.au=Raccah,%20Denis&rft.date=2017-03&rft.volume=33&rft.issue=3&rft.spage=np&rft.epage=n/a&rft.pages=np-n/a&rft.issn=1520-7552&rft.eissn=1520-7560&rft.coden=DMRRFM&rft_id=info:doi/10.1002/dmrr.2858&rft_dat=%3Cproquest_pubme%3E4317662381%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1872780244&rft_id=info:pmid/27606888&rfr_iscdi=true |